{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18"],"submitter":["Hupe M"],"pubmed_abstract":["<h4>Background</h4>As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn's disease (CD), hierarchizing these therapeutic options remains challenging.<h4>Objectives</h4>We aimed to compare the effectiveness of treatments to prevent CD endoscopic POR.<h4>Design</h4>Systematic review and network meta-analysis using a random-effects model.<h4>Data sources and methods</h4>We include studies comparing treatments to prevent CD POR according to PRISMA guidelines. The primary endpoint was endoscopic POR (Rutgeerts score ⩾i2). Surface under the cumulative ranking (SUCRA) was used to hierarchize the treatments.<h4>Results</h4>Twenty studies were included (2414 patients). Overall heterogeneity was moderate (τ = 0.34). Ustekinumab (odds ratio ("],"journal":["Therapeutic advances in gastroenterology"],"pagination":["17562848251374240"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12484893"],"repository":["biostudies-literature"],"pubmed_title":["Systematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn's disease."],"pmcid":["PMC12484893"],"pubmed_authors":["Pereira B","Buisson A","Hupe M"],"additional_accession":[]},"is_claimable":false,"name":"Systematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn's disease.","description":"<h4>Background</h4>As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn's disease (CD), hierarchizing these therapeutic options remains challenging.<h4>Objectives</h4>We aimed to compare the effectiveness of treatments to prevent CD endoscopic POR.<h4>Design</h4>Systematic review and network meta-analysis using a random-effects model.<h4>Data sources and methods</h4>We include studies comparing treatments to prevent CD POR according to PRISMA guidelines. The primary endpoint was endoscopic POR (Rutgeerts score ⩾i2). Surface under the cumulative ranking (SUCRA) was used to hierarchize the treatments.<h4>Results</h4>Twenty studies were included (2414 patients). Overall heterogeneity was moderate (τ = 0.34). Ustekinumab (odds ratio (","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-04T02:23:13.944Z","creation":"2026-05-04T03:13:08.101Z"},"accession":"S-EPMC12484893","cross_references":{"pubmed":["41041281"],"doi":["10.1177/17562848251374240"]}}